Latest Articles

Publication Date
Circulating miRNA as diagnostic tools for gynecological diseases and their applications in biosensor development.

MicroRNAs (miRNAs) have emerged as robust biomarkers for diagnosing and prognosing gynecological diseases due to their disease-specific expression and remarkable stability in body fluids. Despite the inherent instability of RNA …

Published: Nov. 15, 2025, midnight
Definition and criteria for diagnosing primary dysmenorrhea: a modified Delphi procedure.

To achieve consensus on a standardized definition and diagnostic criteria of primary dysmenorrhea.

Published: Nov. 15, 2025, midnight
Global trends in the uptake of specialist diagnostic ultrasound and MRI scans for endometriosis: An international cross-sectional survey.

Endometriosis affects 1 in 10 women globally. We aimed to determine health provider involvement and preferred methods of obtaining an endometriosis diagnosis across international jurisdictions. A global cross-sectional survey, distributed …

Published: Nov. 14, 2025, midnight
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer - Fierce Biotech

Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer Fierce Biotech

Published: Nov. 13, 2025, 9 a.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare

FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare

Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.
Long noncoding RNAs and microRNAs in Endometriosis.

Endometriosis represents a prevalent gynaecological disorder, impacting around 10% of the female population and affecting as many as 50% of women who are facing challenges with infertility. The pathogenesis of …

Published: Nov. 13, 2025, midnight
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer - CancerNetwork

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer CancerNetwork

Published: Nov. 12, 2025, 7:12 p.m.
Gynaecological Devices Market Set to Reach USD 21.11 Billion By 2033, Due to Advances in Surgical and Diagnostic Technologies – SNS Insider - Business Upturn

Gynaecological Devices Market Set to Reach USD 21.11 Billion By 2033, Due to Advances in Surgical and Diagnostic Technologies – SNS Insider Business Upturn

Published: Nov. 12, 2025, 1 p.m.
Proteomics $2.2M R&D rebate to fuel diagnostics test rollout - The Sydney Morning Herald

Proteomics $2.2M R&D rebate to fuel diagnostics test rollout The Sydney Morning Herald

Published: Nov. 12, 2025, 5:39 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!